Linsitinib

Linsitinib

Names
Preferred IUPAC name (1s,3s)-3-[8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
Other names OSI-906
Identifiers
CAS Number	867160-71-2 Y
3D model (JSmol)	Interactive image
ChEBI	CHEBI:91402
ChEMBL	ChEMBL1091644
ChemSpider	21391708
DrugBank	DB06075
KEGG	D09925
PubChem CID	11640390
UNII	15A52GPT8T
CompTox Dashboard (EPA)	DTXSID401007055
InChI InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28) Key: PKCDDUHJAFVJJB-UHFFFAOYSA-N InChI=1/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+ Key: PKCDDUHJAFVJJB-VLZXCDOPBI
SMILES C[C@]1(C[C@@H](C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=CC(=N5)C6=CC=CC=C6)C=C4)O
Properties
Chemical formula	C26H23N5O
Molar mass	421.504 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis.

Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012.

Phase II clinical trials were initiated for multiple myeloma, ovarian cancer, hepatocellular carcinoma, and NSCLC, but subsatisfactory results caused research for these indications to be discontinued. A phase III clinical trial found that linsitinib did not increase survival in patients with adrenocortical carcinoma. As of 2017, no clinical trials were in progress.

External links

• Media related to Linsitinib at Wikimedia Commons